3 Global Pharmaceutical Company, Line Pipes Maker and Power Plant Maintenance Services Company Stocks With a Strong Future Roadmap: Sun Pharma, Welspun Corp and Power Mech Projects
- November 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Sun Pharma, Welspun Corp and Power Mech Projects: ROE of 13.7% to 17.6% and FY22 to FY26 revenue CAGR of 11.6% to 24.4%. Prices as of 9 Nov 2026.
Quick Answer
The three drug major, line pipe and plant service stocks to watch are Sun Pharma, Welspun Corp and Power Mech Projects. Their return on equity ranges from 13.7% to 17.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.6% to 24.4%. Welspun Corp leads on both return on equity at 17.6% and revenue growth at 24.4% a year. Prices are based on the 9 November 2026 close, and this article is educational, not investment advice.
Drug major, line pipe and plant service stocks let investors follow companies that serve a growing part of the Indian economy. Sun Pharma, Welspun Corp and Power Mech Projects cover a global pharmaceutical company, a line pipes maker and a power plant maintenance services company.
This list covers three drug major, line pipe and plant service stocks with complete current figures: Sun Pharma, Welspun Corp and Power Mech Projects. Every figure comes from the latest reported financials and the 9 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Drug Major, Line Pipe and Plant Service Stocks?
Drug major, line pipe and plant service stocks are listed companies that develop and sell generic and specialty medicines worldwide, produce large diameter line pipes for oil, gas and water, and provide operations and maintenance services for power plants. Their earnings depend on prescription demand, pipeline investment and plant service contracts.
Drug Major, Line Pipe and Plant Service Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Sun Pharma | 1,915 | 422,283 | 34.9 | 36.2 | 13.7 | 0.06 |
| Welspun Corp | 2,245.8 | 68,444 | 29.5 | 44.4 | 17.6 | 0.26 |
| Power Mech Projects | 2,405.1 | 7,461 | 17.7 | 22.7 | 14.4 | 0.26 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing drug major, line pipe and plant service stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in drug major, line pipe and plant service stocks can use the coming numbers to test whether growth is holding.
Why Do Drug Major, Line Pipe and Plant Service Stocks Have a Strong Roadmap in India?
Drug major, line pipe and plant service stocks have a strong roadmap in India because steady global demand for medicines, heavy investment in pipelines and a large installed base of power plants needing upkeep keep widening the market for these companies.
- Pharma. Global markets need dependable medicines.
- Line pipes. Pipelines carry oil, gas and water.
- Plant services. Power plants need regular upkeep.
Why Sun Pharma Features Among These Drug Major, Line Pipe and Plant Service Stocks
Among the drug major, line pipe and plant service stocks on this list, Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.
In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%.
Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.
Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What to watch: Track specialty product launches, United States approvals and domestic prescription trends.
Why Welspun Corp Features Among These Drug Major, Line Pipe and Plant Service Stocks
Among the pharma, pipeline and power maintenance shares on this list, Welspun Corp is a large maker of line pipes, stainless steel pipes, ductile iron pipes and plates, with operations in India and the United States, serving oil and gas, water and infrastructure customers.
The company has a return on equity of 17.6%, a debt to equity ratio of 0.26 and a market capitalisation of Rs 68,444 crore. The stock trades at a P/E of 29.5, below the industry P/E of 44.4.
Revenue rose from Rs 7,056 crore in FY22 to Rs 16,905 crore in FY26, a compound annual growth rate of 24.4%. Net profit grew from Rs 444 crore in FY22 to Rs 1,620 crore in FY26, which works out to a compound annual growth rate of 38.2%. In the June 2026 quarter, revenue grew 15.6% year on year to Rs 4,145 crore.
Roadmap: The company holds a strong global position in large-diameter line pipes and is growing in ductile iron pipes for water projects. Its overseas plants and a diversified product range give it exposure to energy and water spending.
What to watch: Monitor the order book in line pipes and the ramp-up of its newer product lines.
Why Power Mech Projects Features Among These Drug Major, Line Pipe and Plant Service Stocks
Among the three companies on this list, Power Mech Projects provides erection, operation and maintenance services to thermal power, renewable energy, infrastructure and industrial clients, working across India and in select overseas markets.
Revenue rose from Rs 2,728 crore in FY22 to Rs 6,107 crore in FY26, a compound annual growth rate of 22.3%. Net profit grew from Rs 138 crore in FY22 to Rs 412 crore in FY26, which works out to a compound annual growth rate of 31.3%.
In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,632 crore, while net profit rose 10.9% to Rs 89.3 crore. The company has a return on equity of 14.4%, a debt to equity ratio of 0.26 and a market capitalisation of Rs 7,461 crore. The stock trades at a P/E of 17.7, below the industry P/E of 22.7.
Roadmap: The company benefits from the build-out of new power capacity and from recurring operation and maintenance contracts, which add stability to earnings. It has also entered infrastructure, railways and metals, widening its order base beyond power.
What to watch: Check the order book composition between power and non-power work and the pace of order inflow.
Sun Pharma vs Welspun Corp vs Power Mech Projects on Key Financials
The table below sets the three drug major, line pipe and plant service stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Sun Pharma | 39,730 | 61,674 | 11.6% | 11,565 | 18.8% |
| Welspun Corp | 7,056 | 16,905 | 24.4% | 1,620 | 9.6% |
| Power Mech Projects | 2,728 | 6,107 | 22.3% | 412 | 6.7% |
Welspun Corp posts the highest return on equity in this group at 17.6%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Welspun Corp shows the fastest revenue growth with a 24.4% compound annual rate. A useful habit with drug major, line pipe and plant service stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several specialty medicine, oil pipe and boiler upkeep stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Sun Pharma | 14,316 | 16,024 | 11.9% |
| Welspun Corp | 3,587 | 4,145 | 15.6% |
| Power Mech Projects | 1,305 | 1,632 | 25.1% |
Key Risks to Check Before Investing in Drug Major, Line Pipe and Plant Service Stocks
Every theme carries risks that deserve a check before any decision. For these drug major, line pipe and plant service stocks, the main points are: Long-term pharma, pipeline and power maintenance shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study pharma, pipeline and power maintenance shares.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Order timing. Project awards can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter drug major, line pipe and plant service stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Drug Major, Line Pipe and Plant Service Stocks
Drug major, line pipe and plant service stocks reward investors who follow demand trends, order books and margins together. Sun Pharma, Welspun Corp and Power Mech Projects each have a clear plan to grow. Based on the 9 November 2026 close, Sun Pharma trades at Rs 1,915, Welspun Corp at Rs 2,245.8 and Power Mech Projects at Rs 2,405.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these drug major, line pipe and plant service stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track drug major, line pipe and plant service stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are drug major, line pipe and plant service stocks?
Ans. Drug major, line pipe and plant service stocks are listed companies that develop and sell generic and specialty medicines worldwide, produce large diameter line pipes for oil, gas and water, and provide operations and maintenance services for power plants. Their earnings depend on prescription demand, pipeline investment and plant service contracts. This list looks at three of them, Sun Pharma, Welspun Corp and Power Mech Projects, using reported FY22 to FY26 financials and the 9 November 2026 closing prices.
Which drug major, line pipe and plant service stocks are covered in this list?
Ans. This list covers Sun Pharma, Welspun Corp and Power Mech Projects. Based on the 9 November 2026 close, Sun Pharma traded at Rs 1,915, Welspun Corp at Rs 2,245.8 and Power Mech Projects at Rs 2,405.1. Their return on equity ranges from 13.7% to 17.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.6% to 24.4%.
Why do drug major, line pipe and plant service stocks have a strong future roadmap in India?
Ans. Drug major, line pipe and plant service stocks have a strong roadmap in India because steady global demand for medicines, heavy investment in pipelines and a large installed base of power plants needing upkeep keep widening the market for these companies. The main drivers are as follows. Pharma. Global markets need dependable medicines. Line pipes. Pipelines carry oil, gas and water. Plant services. Power plants need regular upkeep. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Sun Pharma performed financially?
Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
How has Welspun Corp performed financially?
Ans. Revenue rose from Rs 7,056 crore in FY22 to Rs 16,905 crore in FY26, a compound annual growth rate of 24.4%. Net profit grew from Rs 444 crore in FY22 to Rs 1,620 crore in FY26, which works out to a compound annual growth rate of 38.2%. In the June 2026 quarter, revenue grew 15.6% year on year to Rs 4,145 crore. The company has a return on equity of 17.6%, a debt to equity ratio of 0.26 and a market capitalisation of Rs 68,444 crore. The stock trades at a P/E of 29.5, below the industry P/E of 44.4. Looking ahead, the company holds a strong global position in large-diameter line pipes and is growing in ductile iron pipes for water projects. Its overseas plants and a diversified product range give it exposure to energy and water spending.
How has Power Mech Projects performed financially?
Ans. Revenue rose from Rs 2,728 crore in FY22 to Rs 6,107 crore in FY26, a compound annual growth rate of 22.3%. Net profit grew from Rs 138 crore in FY22 to Rs 412 crore in FY26, which works out to a compound annual growth rate of 31.3%. In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,632 crore, while net profit rose 10.9% to Rs 89.3 crore. The company has a return on equity of 14.4%, a debt to equity ratio of 0.26 and a market capitalisation of Rs 7,461 crore. The stock trades at a P/E of 17.7, below the industry P/E of 22.7. Looking ahead, the company benefits from the build-out of new power capacity and from recurring operation and maintenance contracts, which add stability to earnings. It has also entered infrastructure, railways and metals, widening its order base beyond power.
What risks should investors check before buying drug major, line pipe and plant service stocks?
Ans. Investors should check a few risks before buying drug major, line pipe and plant service stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of drug major, line pipe and plant service stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 9 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
